Regeneron Pharmaceuticals, Inc. (REGN) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Regeneron Pharmaceuticals, Inc. (REGN) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for Regeneron Pharmaceuticals, Inc. (REGN) stock is N/A over the past 12 months. The 3 year average growth rate is 5.40% and the 5 year cagr is 14.13%. Operating cash flow CAGR measures the compound annual growth rate of the cash Regeneron Pharmaceuticals, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
REGN Operating Cash Flow CAGR Chart
Regeneron Pharmaceuticals, Inc. (REGN)
REGN Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $4.42B | $4.98B | +$558.40M | +12.63% | +12.63% |
| 2024 | $4.59B | $4.42B | $-173.50M | -3.78% | -3.78% |
| 2023 | $5.01B | $4.59B | $-420.90M | -8.39% | -8.39% |
| 2022 | $7.08B | $5.01B | $-2.07B | -29.18% | -29.18% |
| 2021 | $2.62B | $7.08B | +$4.46B | +170.47% | +170.47% |
| 2020 | $2.43B | $2.62B | +$188.10M | +7.74% | +7.74% |
| 2019 | $2.20B | $2.43B | +$234.90M | +10.70% | +10.70% |
| 2018 | $1.31B | $2.20B | +$888.00M | +67.94% | +67.94% |
| 2017 | $1.49B | $1.31B | $-178.80M | -12.03% | -12.03% |
| 2016 | $1.33B | $1.49B | +$155.12M | +11.66% | +11.66% |
| 2015 | $752.43M | $1.33B | +$578.35M | +76.86% | +76.86% |
| 2014 | $588.60M | $752.43M | +$163.84M | +27.84% | +27.84% |
| 2013 | $-74.61M | $588.60M | +$663.21M | +0.00% | N/A |
| 2012 | $-141.68M | $-74.61M | +$67.07M | +0.00% | N/A |
| 2011 | $96.34M | $-141.68M | $-238.03M | -247.06% | N/A |
| 2010 | $-72.23M | $96.34M | +$168.57M | +0.00% | N/A |
| 2009 | $-89.09M | $-72.23M | +$16.86M | +0.00% | N/A |
| 2008 | $27.37M | $-89.09M | $-116.46M | -425.46% | N/A |
| 2007 | $23.07M | $27.37M | +$4.30M | +18.62% | +18.62% |
| 2006 | $-30.30M | $23.07M | +$53.37M | +0.00% | N/A |
| 2005 | $-16.91M | $-30.30M | $-13.39M | +0.00% | N/A |
| 2004 | $-6.13M | $-16.91M | $-10.78M | +0.00% | N/A |
| 2003 | $-110.52M | $-6.13M | +$104.39M | +0.00% | N/A |
| 2002 | $-57.32M | $-110.52M | $-53.20M | +0.00% | N/A |
| 2001 | $-27.91M | $-57.32M | $-29.41M | +0.00% | N/A |
| 2000 | $-13.80M | $-27.91M | $-14.11M | +0.00% | N/A |
| 1999 | $-10.20M | $-13.80M | $-3.60M | +0.00% | N/A |
| 1998 | $-6.10M | $-10.20M | $-4.10M | +0.00% | N/A |
| 1997 | $-20.30M | $-6.10M | +$14.20M | +0.00% | N/A |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer